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formulation, since the tricyclic drugs interfere with re-uptake of noradrenaline into noradrenergic nerves, while the monoamine oxidase inhibitors interfere with its deamination, so increasing the amount of transmitter at receptors. There is recent evidence that monomethylated tricyclic compounds-for example, nortriptyline, and desipramine-affect brain noradrenaline metabolism but not that of 5-HT and dopamine, whereas the dimethylated compounds, amitryptiline and imipramine, affect only 5-HT metabolism. Use of tricyclic drugs has been of great help to pharmacologists in studying the fate of noradrenaline after its release (Iversen, 1971) , partly by re-uptake into noradrenergic nerves (uptake mechanismi) and partly by uptake by non-neuronal tissues (uptake mechanism2).
The 'indoleamine' hypothesis poses a 'deficiency', in depression, of 5-HT at central nervous receptors. Consequently, it would be logical to prescribe the 5-HT precursor, 5-hydroxytryptophan (5-HTP), or the tricyclic drugs which also reduce re-uptake of 5-HT, after its release, back into 5-hydroxytryptaminergic nerves. However, 5-HTP proved ineffective for depression and while there is debate as to the efficacy of tryptophan (Carroll, 1971) , there seems agreement that tryptophan potentiates the anti-depressant actions of an MAOI. The 'indoleamine' hypothesis attributes mania to 'excess' 5-HT at central receptors, indicating treatment either by inhibiting the enzyme converting 5-HTP to 5-HT (thereby also interfering with decarboxylation of DOPA) or with a 5-HT antagonist such as methysergide, for which beneficial claims have been made (Dewhurst, 1968) . It should be borne in mind that these 'excesses' and 'deficiencies' of central transmitters are extrapolations based on the concentration of transmitter metabolites in the cerebrospinal fluid-or, considerably less pertinent, in the urine.
Research into schizophrenia, a disorder with auditory rather than visual hallucinations, has been dogged by the appearance of chromatographic 'spots' before the eyes. These phenomena, hopefully claimed as metabolites specific to schizophrenia, have proved non-specific on stricter appraisal. Of interest are reports that methylation, a chemical transformation used by the body and resorted to by chemists and pharmacologists in structure-activity studies, is abnormal in schizophrenics. The idea is supported by findings that exhibition of methyl donors such as betaine or methionine leads to exacerbation of schizophrenic 'nuclear' symptoms. There has been speculation as to the relation between schizophrenia, 'model' psychoses induced by hallucinogens, and the effects of hallucinogens and phenothiazines on the central actions of 5-HT and catecholamines. However, chemical theories to account for schizophrenia, although ingenious, are less substantially based than those for affective illness. Amphetamine addiction can produce a clinical picture simulating paranoid schizophrenia (Connell, 1958) . Amphetamine acts by releasing intraneuronal noradrenaline and dopamine, by interfering with their re-uptake into nerves, by inhibiting monoamine oxidase, and by virtue of its tryptamine-like properties. Hallucinations, following amphetamine, have been ascribed to its 'tryptamimetic' properties (Vane, 1960) and, indeed, a number of tryptamines are hallucinogenic.
Paradoxically and happily, one facet of the 'drug revolution' is that patients with psychoses become both accessible to and benefit from social and psychological treatments, an approach that would have been regarded as unwarrantable by most psychiatrists two decades ago. Consequently, adherence to pharmacotherapy should in no way neglect the milieu in which the illness throve.
Though claims for a therapeutic miracle have been made, there are no grounds for complacency. There is a need for improved drugs and it is disappointing that, after the breakthrough in the 1950s, there has been consolidation rather than advance. New drugs have appeared but are variants of already accepted tricyclic substances (including phenothiazines). While tricyclic drugs have proved more satisfactory than the monoamine oxidase inhibitors for treating depression, it would be unwise to ignore recent leads-for example, the discovery that monoamine oxidase consists of a number of isoenzymes. This stimulated search for a clinically effective MAOI which did not inhibit the isoenzyme deaminating tyramine, hence avoiding the 'hypertensive crisis' which developed in some patients on MAOI after ingestion of certain foods.
Although to be deplored, such side-effects should be scrutinized closely, since they provide clues as to the mode of action of a drug and often open new areas or research. The 'hypertensive crisis' after eating cheese (Blackwell, 1963 ) is one such example, and led to considerably greater understanding of the pharmacology of foods containing amines and their precursors. Another example-extrapyramidal disorders associated with reserpine, phenothiazine, or butypherone administration-was found to be associated with blockade of central dopamine receptors and increased dopamine turnover in the nervous system. Apart from providing an animal model with which to study extrapyramidal disorders, these findings, combined with the knowledge that Parkinson's disease, due to a variety of causes, is associated with degeneration of and loss of dopamine from striatal neurones, provided impetus for its treatment with DOPA.
Lest it be thought that progress has been confined to psychoses, one might mention the value of propranolol, an antagonist at /?-adrenoreceptors, in patients with anxiety and autonomic symptoms, and of the benzodiazepines in patients with anxiety accompanied by feelings of tension.
These, then, are some of the consequences of the cross-fertilization of psychiatry with pharmacology. There can be little doubt that the liaison has been fruitful; indeed, there are grounds for suspecting concubinage with other disciplines.
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